ALENDRONATE MAY LOWER CARDIOVASCULAR RISK IN PATIENTS WITH HIP FRACTURE

摘要

The osteoporosis treatment alendronate may reduce the risk of cardiovascular events in people with hip fractures, according to a study published in the Journal of Bone and Mineral Research (9 May 2018). The study looked at patients diagnosed with a hip fracture in Hong Kong between 2005 and 2013 who were followed up until 2016, including 4,594 patients exposed to anti-osteoporosis medication (3,081 patients to alendronate) matched with 13,568 untreated patients.